Skip to main content
OpenTrials
Completed

NCT Number: NCT04490850

COVID-19 Seroprevalence Study in French Guiana

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronavirus Infection COVID-19 Coronaviridae Infections Coronavirus Infections Covid19 Infections Lung Diseases Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections SARS-CoV Infection Severe Acute Respiratory Syndrome Virus Diseases

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier Andrée Rosemon, Cayenne, French Guiana

Loading trial locations.

About this study

Serological surveys measuring anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies in the population to assess the extent of the infection and the COVID-19 immunity of the population in French Guiana.

This study is a interventional study that present minimal risks and constraints.

The results of the study will allow estimation of COVID-19 virus infection, severity and attack rates, as well as inform public health responses and policy decisions in the French Guiana territory.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Person going to a prevention and care center or medical biology analysis laboratory as part of the care, regardless age, regardless of an acute or previous infection with COVID-19;
  • State of health compatible with a blood sample as defined in the protocol

Exclusion criteria

  • Inability to consent
  • Person under guardianship or curatorship
  • Known pathology or a health problem contraindicated with the collect of blood sample.

Treatment and study plan

Blood sample

Procedure

Blood sample

Primary outcomes

  1. Measure of the COVID-19 immunity of the population

    Time frame: 1 year

    The COVID-19 immunity of the population will be assessed by evaluating the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies

Secondary outcomes

  1. Evaluation of the level of asymptomatic and pauci-symptomatic infections

    Time frame: 1 year

    The proportion of asymptomatic and pauci-symptomatic infections will be measured in the population

Sponsors and collaborators

Lead sponsor

Institut Pasteur

Industry

Collaborators

  • Centres Délocalisés de Prévention et de Soins, Centre Hospitalier Andrée Rosemon de Cayenne, Frech Guiana
  • Eurofins
  • Institut Pasteur de la Guyane
  • Laboratoire de biologie médicale de Kourou, French Guiana
  • Laboratoire de biologie médicale du Centre hospitalier de Saint-Laurent du Maroni, French Guiana
  • Laboratoire de biologie médicale, Institut Pasteur de la Guyane

Registry information

Acronym: EPI-COVID-POP

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jul 29, 2020
Registry last updated
Feb 15, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.